表紙
市場調查報告書
商品編碼
1070507

BCG 疫苗全球市場機會分析和行業預測:按人口統計(兒童(0-18 歲)、成人(19-35 歲))(2021-2030)

BCG Vaccine Market by Demographics (Pediatric (0-18 Years) and Adults (19-35 Years): Global Opportunity Analysis and Industry Forecast, 2021-2030

出版日期: | 出版商: Allied Market Research | 英文 165 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球卡介苗疫苗市場預計將從 2020 年的 46,637,500 美元增長到 2030 年的 74,269,550 美元,預測期內復合年增長率為 4.8%。

全球卡介苗疫苗市場受到結核病患病率增加和疫苗研究技術不斷進步的推動。此外,政府加大力度和全球對免疫計劃的關注正在推動市場增長。

本報告研究和分析了全球卡介苗疫苗市場,並提供了市場狀況、市場分析和企業概況等系統信息。

目錄

第1章介紹

第2章執行摘要

第3章市場情況

  • 市場定義和範圍
  • 主要調查結果
    • 主要投資領域
    • 主要成功策略
  • 波特五力分析
    • 供應商的議價能力
    • 新進入者的威脅
    • 替代威脅
    • 競爭對手之間的敵對關係
    • 買家之間的談判權
  • 市場份額分析/主要公司定位
    • 市場份額分析/主要公司定位(2020)
  • 市場動態
    • 促進因素
    • 抑制器
    • 市場機會
  • COVID-19 影響分析

第 4 章 BCG 疫苗市場:按人口統計

  • 市場概況
  • 市場規模和預測:按人口統計
  • 兒童(0-18歲)
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區
    • 市場份額分析:按國家/地區分類
  • 成人(19-35歲)
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區
    • 市場份額分析:按國家/地區分類

第 5 章 BCG 疫苗市場:按地區劃分

  • 市場概況
  • 市場規模和預測:按地區
  • 亞太地區
    • 主要市場趨勢和機遇
    • 市場規模和預測:按人口統計
    • 市場規模和預測:按國家/地區分類
    • 印度卡介苗疫苗市場
      • 市場規模和預測:按人口統計
    • 中國卡介苗市場
      • 市場規模和預測:按人口統計
    • 孟加拉國卡介苗疫苗市場
      • 市場規模和預測:按人口統計
    • 巴基斯坦卡介苗疫苗市場
      • 市場規模和預測:按人口統計
    • 印尼卡介苗疫苗市場
      • 市場規模和預測:按人口統計
    • 日本卡介苗疫苗市場
      • 市場規模和預測:按人口統計
    • 泰國卡介苗疫苗市場
      • 市場規模和預測:按人口統計
    • 新加坡的卡介苗疫苗市場
      • 市場規模和預測:按人口統計
    • 其他亞太地區 BCG 疫苗市場
      • 市場規模和預測:按人口統計
  • 拉丁美洲/中東/非洲
    • 主要市場趨勢和機遇
    • 市場規模和預測:按人口統計
    • 市場規模和預測:按國家/地區分類
    • 巴西卡介苗疫苗市場
      • 市場規模和預測:按人口統計
    • 墨西哥卡介苗疫苗市場
      • 市場規模和預測:按人口統計
    • 南非卡介苗疫苗市場
      • 市場規模和預測:按人口統計
    • 肯尼亞的卡介苗疫苗市場
      • 市場規模和預測:按人口統計
    • 阿根廷的卡介苗疫苗市場
      • 市場規模和預測:按人口統計
    • 哥倫比亞卡介苗疫苗市場
      • 市場規模和預測:按人口統計
    • 智利卡介苗疫苗市場
      • 市場規模和預測:按人口統計
    • 其他拉丁美洲/中東/非洲 BCG 疫苗市場
      • 市場規模和預測:按人口統計
  • 其他
    • 主要市場趨勢和機遇
    • 市場規模和預測:按人口統計

第 6 章公司簡介

  • AJ Biologics
  • China National Group Corporation(Sinopharm)
  • Greensignal Biopharma Limited
  • Intervax Ltd.
  • Japan BCG Laboratory
  • Merck And Co., Inc.
  • Sanofi
  • Serum Institute Of India Pvt. Ltd.
  • Stetens Serum Institute
  • Torlak Institute Of Virology
目錄
Product Code: LI_174419 / A04070

The global BCG vaccine market was valued at $46,637.5 thousands in 2020, and is projected to reach $74,269.55 thousands by 2030, registering a CAGR of 4.8% from 2021 to 2030.

Bacillus Calmette-Guerin (BCG) vaccine is the only vaccine available for the prevention of human forms of tuberculosis (TB). This vaccine is generally administered to children at birth in countries with high incidence of TB. In regions with low level of TB, only children at high risk are typically immunized, whereas adults are generally not immunized. However, adults (up to the age of 35) who are frequently exposed to drug-resistant TB may also be given BCG vaccine.

The global BCG vaccine market is driven by increase in prevalence of tuberculosis and rise in technological advancements in vaccine research. Moreover, the increase in government initiatives and focus on immunization programs globally boost the market growth. However, side effects of BCG vaccine and the global shortage of BCG vaccine restrain this growth. Untapped market potential in developing regions are expected to present numerous opportunities for market development during the forecast period.

The BCG vaccine market is segmented on the basis of demographics, and region. On the basis of demographics, it is bifurcated into pediatrics (0-18 Years) and Adults (19-35 years). Region wise, the market is analyzed across Asia-Pacific, LAMEA, and Rest of the World.

KEY BENEFITS FOR STAKEHOLDERS

  • This report provides a detailed quantitative analysis of the current market trends and future estimations from 2020 to 2030, which assists to identify the prevailing market opportunities.
  • An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
  • A comprehensive analysis of the factors that drive and restrain the growth of the BCG vaccine market is provided.
  • An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.

KEY MARKET SEGMENTS

  • By Demographic Type
    • Pediatrics (0-18 Years)
    • Adults (19-35 Years)
  • By Region
    • Asia Pacific
      • India
      • China
      • Bangladesh
      • Pakistan
      • Indonesia
      • Japan
      • Thailand
      • Singapore
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • Mexico
      • South Africa
      • Kenya
      • Argentina
      • Colombia
      • Chile
      • Rest of LAMEA
    • REST OF THE WORLD

KEY MARKET PLAYERS

  • AJ Biologics
  • China National group corporation (Sinopharm)
  • Greensignal Biopharma Limited
  • Intervax Ltd.
  • Japan BCG Laboratory
  • Merck & Co., Inc.
  • Sanofi
  • Serum Institute of India Pvt. Ltd.
  • Stetens Serum Institute
  • Torlak Institute of Virology

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1.Report Description
  • 1.2.Key Market Segments
  • 1.3.Key Benefits
  • 1.4.Research Methodology
    • 1.4.1.Primary Research
    • 1.4.2.Secondary Research
    • 1.4.3.Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1.CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1.Market Definition and Scope
  • 3.2.Key Findings
    • 3.2.1.Top Investment Pockets
    • 3.2.2.Top Winning Strategies
  • 3.3.Porter's Five Forces Analysis
    • 3.3.1.Bargaining Power of Suppliers
    • 3.3.2.Threat of New Entrants
    • 3.3.3.Threat of Substitutes
    • 3.3.4.Competitive Rivalry
    • 3.3.5.Bargaining Power among Buyers
  • 3.4.Market Share Analysis/Top Player Positioning
    • 3.4.1.Market Share Analysis/Top Player Positioning 2020
  • 3.5.Market Dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6. COVID-19 Impact Analysis

CHAPTER 4: BCG VACCINE MARKET, BY DEMOGRAPHICS

  • 4.1.Market Overview
  • 4.1.1Market Size and Forecast, By Demographics
  • 4.2.PEDIATRICS (AGE 0-18 YEARS)
    • 4.2.1.Key Market Trends, Growth Factors and Opportunities
    • 4.2.2.Market Size and Forecast, By Region
    • 4.2.3.Market Share Analysis, By Country
  • 4.3.ADULTS (AGE 19-35 YEARS)
    • 4.3.1.Key Market Trends, Growth Factors and Opportunities
    • 4.3.2.Market Size and Forecast, By Region
    • 4.3.3.Market Share Analysis, By Country

CHAPTER 5: BCG VACCINE MARKET, BY REGION

  • 5.1.Market Overview
  • 5.1.1Market Size and Forecast, By Region
  • 5.2.Asia-Pacific
    • 5.2.1.Key Market Trends and Opportunities
    • 5.2.2.Market Size and Forecast, By Demographics
    • 5.2.3.Market Size and Forecast, By Country
    • 5.2.4.India BCG Vaccine Market
      • 5.2.4.1.Market Size and Forecast, By Demographics
    • 5.2.5.China BCG Vaccine Market
      • 5.2.5.1.Market Size and Forecast, By Demographics
    • 5.2.6.Bangladesh BCG Vaccine Market
      • 5.2.6.1.Market Size and Forecast, By Demographics
    • 5.2.7.Pakistan BCG Vaccine Market
      • 5.2.7.1.Market Size and Forecast, By Demographics
    • 5.2.8.Indonesia BCG Vaccine Market
      • 5.2.8.1.Market Size and Forecast, By Demographics
    • 5.2.9.Japan BCG Vaccine Market
      • 5.2.9.1.Market Size and Forecast, By Demographics
    • 5.2.10.Thailand BCG Vaccine Market
      • 5.2.10.1.Market Size and Forecast, By Demographics
    • 5.2.11.Singapore BCG Vaccine Market
      • 5.2.11.1.Market Size and Forecast, By Demographics
    • 5.2.12.Rest Of Asia-pacific BCG Vaccine Market
      • 5.2.12.1.Market Size and Forecast, By Demographics
  • 5.3.LAMEA
    • 5.3.1.Key Market Trends and Opportunities
    • 5.3.2.Market Size and Forecast, By Demographics
    • 5.3.3.Market Size and Forecast, By Country
    • 5.3.4.Brazil BCG Vaccine Market
      • 5.3.4.1.Market Size and Forecast, By Demographics
    • 5.3.5.Mexico BCG Vaccine Market
      • 5.3.5.1.Market Size and Forecast, By Demographics
    • 5.3.6.South Africa BCG Vaccine Market
      • 5.3.6.1.Market Size and Forecast, By Demographics
    • 5.3.7.Kenya BCG Vaccine Market
      • 5.3.7.1.Market Size and Forecast, By Demographics
    • 5.3.8.Argentina BCG Vaccine Market
      • 5.3.8.1.Market Size and Forecast, By Demographics
    • 5.3.9.Colombia BCG Vaccine Market
      • 5.3.9.1.Market Size and Forecast, By Demographics
    • 5.3.10.Chile BCG Vaccine Market
      • 5.3.10.1.Market Size and Forecast, By Demographics
    • 5.3.11.Rest of LAMEA BCG Vaccine Market
      • 5.3.11.1.Market Size and Forecast, By Demographics
  • 5.4.Rest of the World
    • 5.4.1.Key Market Trends and Opportunities
    • 5.4.2.Market Size and Forecast, By Demographics

CHAPTER 6: COMPANY PROFILES

  • 6.1.AJ Biologics
    • 6.1.1.Company Overview
    • 6.1.2.Key Executives
    • 6.1.3.Company snapshot
    • 6.1.4.Operating business segments
    • 6.1.5.Product portfolio
    • 6.1.6.Business Performance
    • 6.1.7.Key Strategic Moves and Developments
  • 6.2.China National Group Corporation (Sinopharm)
    • 6.2.1.Company Overview
    • 6.2.2.Key Executives
    • 6.2.3.Company snapshot
    • 6.2.4.Operating business segments
    • 6.2.5.Product portfolio
    • 6.2.6.Business Performance
    • 6.2.7.Key Strategic Moves and Developments
  • 6.3.Greensignal Biopharma Limited
    • 6.3.1.Company Overview
    • 6.3.2.Key Executives
    • 6.3.3.Company snapshot
    • 6.3.4.Operating business segments
    • 6.3.5.Product portfolio
    • 6.3.6.Business Performance
    • 6.3.7.Key Strategic Moves and Developments
  • 6.4.Intervax Ltd.
    • 6.4.1.Company Overview
    • 6.4.2.Key Executives
    • 6.4.3.Company snapshot
    • 6.4.4.Operating business segments
    • 6.4.5.Product portfolio
    • 6.4.6.Business Performance
    • 6.4.7.Key Strategic Moves and Developments
  • 6.5.Japan BCG Laboratory
    • 6.5.1.Company Overview
    • 6.5.2.Key Executives
    • 6.5.3.Company snapshot
    • 6.5.4.Operating business segments
    • 6.5.5.Product portfolio
    • 6.5.6.Business Performance
    • 6.5.7.Key Strategic Moves and Developments
  • 6.6.Merck And Co., Inc.
    • 6.6.1.Company Overview
    • 6.6.2.Key Executives
    • 6.6.3.Company snapshot
    • 6.6.4.Operating business segments
    • 6.6.5.Product portfolio
    • 6.6.6.Business Performance
    • 6.6.7.Key Strategic Moves and Developments
  • 6.7.Sanofi
    • 6.7.1.Company Overview
    • 6.7.2.Key Executives
    • 6.7.3.Company snapshot
    • 6.7.4.Operating business segments
    • 6.7.5.Product portfolio
    • 6.7.6.Business Performance
    • 6.7.7.Key Strategic Moves and Developments
  • 6.8.Serum Institute Of India Pvt. Ltd.
    • 6.8.1.Company Overview
    • 6.8.2.Key Executives
    • 6.8.3.Company snapshot
    • 6.8.4.Operating business segments
    • 6.8.5.Product portfolio
    • 6.8.6.Business Performance
    • 6.8.7.Key Strategic Moves and Developments
  • 6.9.Stetens Serum Institute
    • 6.9.1.Company Overview
    • 6.9.2.Key Executives
    • 6.9.3.Company snapshot
    • 6.9.4.Operating business segments
    • 6.9.5.Product portfolio
    • 6.9.6.Business Performance
    • 6.9.7.Key Strategic Moves and Developments
  • 6.10.Torlak Institute Of Virology
    • 6.10.1.Company Overview
    • 6.10.2.Key Executives
    • 6.10.3.Company snapshot
    • 6.10.4.Operating business segments
    • 6.10.5.Product portfolio
    • 6.10.6.Business Performance
    • 6.10.7.Key Strategic Moves and Developments

LIST OF TABLES

  • TABLE 1.GLOBAL BCG VACCINE MARKET, BY DEMOGRAPHICS, 2020-2030 ($MILLION)
  • TABLE 2.GLOBAL BCG VACCINE MARKET FOR PEDIATRICS (AGE 0-18 YEARS), BY REGION, 2020-2030 ($MILLION)
  • TABLE 3.GLOBAL BCG VACCINE MARKET FOR ADULTS (AGE 19-35 YEARS), BY REGION, 2020-2030 ($MILLION)
  • TABLE 4.GLOBAL BCG VACCINE MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 5.ASIA-PACIFIC BCG VACCINE, BY DEMOGRAPHICS, 2020-2030 ($MILLION)
  • TABLE 6.INDIA BCG VACCINE, BY DEMOGRAPHICS, 2020-2030 ($MILLION)
  • TABLE 7.CHINA BCG VACCINE, BY DEMOGRAPHICS, 2020-2030 ($MILLION)
  • TABLE 8.BANGLADESH BCG VACCINE, BY DEMOGRAPHICS, 2020-2030 ($MILLION)
  • TABLE 9.PAKISTAN BCG VACCINE, BY DEMOGRAPHICS, 2020-2030 ($MILLION)
  • TABLE 10.INDONESIA BCG VACCINE, BY DEMOGRAPHICS, 2020-2030 ($MILLION)
  • TABLE 11.JAPAN BCG VACCINE, BY DEMOGRAPHICS, 2020-2030 ($MILLION)
  • TABLE 12.THAILAND BCG VACCINE, BY DEMOGRAPHICS, 2020-2030 ($MILLION)
  • TABLE 13.SINGAPORE BCG VACCINE, BY DEMOGRAPHICS, 2020-2030 ($MILLION)
  • TABLE 14.REST OF ASIA-PACIFIC BCG VACCINE, BY DEMOGRAPHICS, 2020-2030 ($MILLION)
  • TABLE 15.LAMEA BCG VACCINE, BY DEMOGRAPHICS, 2020-2030 ($MILLION)
  • TABLE 16.BRAZIL BCG VACCINE, BY DEMOGRAPHICS, 2020-2030 ($MILLION)
  • TABLE 17.MEXICO BCG VACCINE, BY DEMOGRAPHICS, 2020-2030 ($MILLION)
  • TABLE 18.SOUTH AFRICA BCG VACCINE, BY DEMOGRAPHICS, 2020-2030 ($MILLION)
  • TABLE 19.KENYA BCG VACCINE, BY DEMOGRAPHICS, 2020-2030 ($MILLION)
  • TABLE 20.ARGENTINA BCG VACCINE, BY DEMOGRAPHICS, 2020-2030 ($MILLION)
  • TABLE 21.COLOMBIA BCG VACCINE, BY DEMOGRAPHICS, 2020-2030 ($MILLION)
  • TABLE 22.CHILE BCG VACCINE, BY DEMOGRAPHICS, 2020-2030 ($MILLION)
  • TABLE 23.REST OF LAMEA BCG VACCINE, BY DEMOGRAPHICS, 2020-2030 ($MILLION)
  • TABLE 24.REST OF THE WORLD BCG VACCINE, BY DEMOGRAPHICS, 2020-2030 ($MILLION)
  • TABLE 25.AJ BIOLOGICS: KEY EXECUTIVES
  • TABLE 26.AJ BIOLOGICS: COMPANY SNAPSHOT
  • TABLE 27.AJ BIOLOGICS: OPERATING SEGMENTS
  • TABLE 28.AJ BIOLOGICS: PRODUCT PORTFOLIO
  • TABLE 29.AJ BIOLOGICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 30.CHINA NATIONAL GROUP CORPORATION (SINOPHARM): KEY EXECUTIVES
  • TABLE 31.CHINA NATIONAL GROUP CORPORATION (SINOPHARM): COMPANY SNAPSHOT
  • TABLE 32.CHINA NATIONAL GROUP CORPORATION (SINOPHARM): OPERATING SEGMENTS
  • TABLE 33.CHINA NATIONAL GROUP CORPORATION (SINOPHARM): PRODUCT PORTFOLIO
  • TABLE 34.CHINA NATIONAL GROUP CORPORATION (SINOPHARM): KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 35.GREENSIGNAL BIOPHARMA LIMITED: KEY EXECUTIVES
  • TABLE 36.GREENSIGNAL BIOPHARMA LIMITED: COMPANY SNAPSHOT
  • TABLE 37.GREENSIGNAL BIOPHARMA LIMITED: OPERATING SEGMENTS
  • TABLE 38.GREENSIGNAL BIOPHARMA LIMITED: PRODUCT PORTFOLIO
  • TABLE 39.GREENSIGNAL BIOPHARMA LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 40.INTERVAX LTD.: KEY EXECUTIVES
  • TABLE 41.INTERVAX LTD.: COMPANY SNAPSHOT
  • TABLE 42.INTERVAX LTD.: OPERATING SEGMENTS
  • TABLE 43.INTERVAX LTD.: PRODUCT PORTFOLIO
  • TABLE 44.INTERVAX LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 45.JAPAN BCG LABORATORY: KEY EXECUTIVES
  • TABLE 46.JAPAN BCG LABORATORY: COMPANY SNAPSHOT
  • TABLE 47.JAPAN BCG LABORATORY: OPERATING SEGMENTS
  • TABLE 48.JAPAN BCG LABORATORY: PRODUCT PORTFOLIO
  • TABLE 49.JAPAN BCG LABORATORY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 50.MERCK AND CO., INC.: KEY EXECUTIVES
  • TABLE 51.MERCK AND CO., INC.: COMPANY SNAPSHOT
  • TABLE 52.MERCK AND CO., INC.: OPERATING SEGMENTS
  • TABLE 53.MERCK AND CO., INC.: PRODUCT PORTFOLIO
  • TABLE 54.MERCK AND CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 55.SANOFI: KEY EXECUTIVES
  • TABLE 56.SANOFI: COMPANY SNAPSHOT
  • TABLE 57.SANOFI: OPERATING SEGMENTS
  • TABLE 58.SANOFI: PRODUCT PORTFOLIO
  • TABLE 59.SANOFI: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 60.SERUM INSTITUTE OF INDIA PVT. LTD.: KEY EXECUTIVES
  • TABLE 61.SERUM INSTITUTE OF INDIA PVT. LTD.: COMPANY SNAPSHOT
  • TABLE 62.SERUM INSTITUTE OF INDIA PVT. LTD.: OPERATING SEGMENTS
  • TABLE 63.SERUM INSTITUTE OF INDIA PVT. LTD.: PRODUCT PORTFOLIO
  • TABLE 64.SERUM INSTITUTE OF INDIA PVT. LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 65.STETENS SERUM INSTITUTE: KEY EXECUTIVES
  • TABLE 66.STETENS SERUM INSTITUTE: COMPANY SNAPSHOT
  • TABLE 67.STETENS SERUM INSTITUTE: OPERATING SEGMENTS
  • TABLE 68.STETENS SERUM INSTITUTE: PRODUCT PORTFOLIO
  • TABLE 69.STETENS SERUM INSTITUTE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 70.TORLAK INSTITUTE OF VIROLOGY: KEY EXECUTIVES
  • TABLE 71.TORLAK INSTITUTE OF VIROLOGY: COMPANY SNAPSHOT
  • TABLE 72.TORLAK INSTITUTE OF VIROLOGY: OPERATING SEGMENTS
  • TABLE 73.TORLAK INSTITUTE OF VIROLOGY: PRODUCT PORTFOLIO
  • TABLE 74.TORLAK INSTITUTE OF VIROLOGY: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

  • FIGURE 1.GLOBAL BCG VACCINE MARKET SEGMENTATION
  • FIGURE 2.GLOBAL BCG VACCINE MARKET
  • FIGURE 3.SEGMENTATION BCG VACCINE MARKET
  • FIGURE 4.TOP INVESTMENT POCKET IN BCG VACCINE MARKET
  • FIGURE 5.TOP WINNING STRATEGIES, 2019-2021*
  • FIGURE 6.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2019-2021(%)
  • FIGURE 7.TOP WINNING STRATEGIES, BY COMPANY, 2019-2021*
  • FIGURE 8.MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 9.MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 10.MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 11.LOW THREAT OF SUBSTITUTION
  • FIGURE 12.HIGH COMPETITIVE RIVALRY
  • FIGURE 13.TOP PLAYER POSITIONING, 2020
  • FIGURE 14.MARKET SHARE ANALYSIS, 2020
  • FIGURE 15.RESTRAINTS AND DRIVERS: BCG VACCINE MARKET
  • FIGURE 16.BCG VACCINE MARKET SEGMENTATION, BY DEMOGRAPHICS
  • FIGURE 17.BCG VACCINE MARKET FOR PEDIATRICS (AGE 0-18 YEARS), BY COUNTRY, 2020-2030 ($MILLION)
  • FIGURE 18.BCG VACCINE MARKET FOR ADULTS (AGE 19-35 YEARS), BY COUNTRY, 2020-2030 ($MILLION)
  • FIGURE 19.AJ BIOLOGICS: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 20.AJ BIOLOGICS: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 21.AJ BIOLOGICS: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 22.CHINA NATIONAL GROUP CORPORATION (SINOPHARM): NET SALES, 2018-2020 ($MILLION)
  • FIGURE 23.CHINA NATIONAL GROUP CORPORATION (SINOPHARM): REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 24.CHINA NATIONAL GROUP CORPORATION (SINOPHARM): REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 25.GREENSIGNAL BIOPHARMA LIMITED: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 26.GREENSIGNAL BIOPHARMA LIMITED: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 27.GREENSIGNAL BIOPHARMA LIMITED: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 28.INTERVAX LTD.: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 29.INTERVAX LTD.: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 30.INTERVAX LTD.: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 31.JAPAN BCG LABORATORY: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 32.JAPAN BCG LABORATORY: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 33.JAPAN BCG LABORATORY: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 34.MERCK AND CO., INC.: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 35.MERCK AND CO., INC.: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 36.MERCK AND CO., INC.: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 37.SANOFI: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 38.SANOFI: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 39.SANOFI: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 40.SERUM INSTITUTE OF INDIA PVT. LTD.: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 41.SERUM INSTITUTE OF INDIA PVT. LTD.: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 42.SERUM INSTITUTE OF INDIA PVT. LTD.: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 43.STETENS SERUM INSTITUTE: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 44.STETENS SERUM INSTITUTE: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 45.STETENS SERUM INSTITUTE: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 46.TORLAK INSTITUTE OF VIROLOGY: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 47.TORLAK INSTITUTE OF VIROLOGY: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 48.TORLAK INSTITUTE OF VIROLOGY: REVENUE SHARE, BY REGION, 2020 (%)